XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.33

-1.9%

Dec 17 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (15864)	7/13/2002 12:54:04 PM
From: Cacaito	Read Replies (1) of 17367

This time it comes with a "contingent" caveat: "Xanelim™ (Efalizumab): Genentech met with the FDA during the second quarter of 2002 to discuss the Xanelim filing strategy. Contingent upon a positive outcome in the ongoing Phase III efficacy trial using Genentech material, the company will plan on filing a Biologic License Application to the FDA by the fourth quarter of this year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next